A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. Company Overview We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The unique therapeutic constructs also enable the simultaneous delivery of wildtype replacement genes, facilitating the proprietary “silence and replace” approach to the treatment of genetically defined diseases.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 73K | - | - |
| Net Income | -46M | -22M | -20M | - | -14M | -8.3M |
| EPS | $-0.77 | $-5.51 | $-14.12 | $-37.88 | $-54.91 | $-137.70 |
| Free Cash Flow | 0 | -20M | -18M | -16M | -13M | -7.6M |
| ROIC | -20.9% | -47.3% | -7462.4% | - | -69.4% | -80.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.11 | 21.10 | 1.07 | 0.07 | 0.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -51M | -22M | -19M | -18M | -14M | -8.3M |
| Operating Margin | 0.0% | - | - | -24457.5% | - | - |
| ROE | -24.7% | -94.3% | -9684.2% | - | -69.4% | -80.8% |
| Shares Outstanding | 34M | 11M | 11M | 3M | 0M | 0M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 12M | N/A | N/A | 73K | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 4.6M | 3.0M | 7.0M | 11M | 13M | 16M | 19M |
| SG&A | 4.6M | 5.6M | 6.5M | 6.6M | 6.4M | 7.0M | 32M |
| EBIT | 2.6M | -8.3M | -14M | -18M | -19M | -22M | -51M |
| Op. Margin | 21.2% | N/A | N/A | -24457.5% | N/A | N/A | 0.0% |
| Net Income | N/A | -8.3M | -14M | N/A | -20M | -22M | -46M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/A | -80.8% | -69.4% | N/A | N/M | -47.3% | -20.9% |
| ROE | N/A | -80.8% | -69.4% | N/A | -9684.2% | -94.3% | -24.7% |
| ROA | N/A | -71.4% | -64.9% | N/A | -438.2% | -78.9% | -24.3% |
| Cash Flow | |||||||
| Op. Cash Flow | 4.8M | -7.5M | -13M | -16M | -18M | -19M | -18M |
| Free Cash Flow | 4.4M | -7.6M | -13M | -16M | -18M | -20M | 0 |
| Owner Earnings | 4.0M | -8.0M | -14M | -17M | -19M | -20M | -47M |
| CapEx | 404K | 95K | 221K | 13K | 1K | 179K | 0 |
| Maint. CapEx | 158K | 190K | 231K | 167K | 136K | 87K | 54K |
| Growth CapEx | 246K | 0 | 0 | 0 | 0 | 92K | 0 |
| D&A | 158K | 190K | 231K | 167K | 136K | 87K | 54K |
| CapEx/OCF | 8.4% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 672K | 237K | 634K | 870K | 452K | 830K | 29M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -378M |
| Cash & Equiv. | 16M | 9.8M | 20M | 4.1M | 13K | 63K | 378M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.16 | 0.13 | 0.07 | 1.07 | 21.10 | 0.11 | 0.00 |
| Interest Coverage | 21.2 | -133.6 | -2266.0 | -557.9 | -578.2 | -24.9 | -24.9 |
| Equity | 17M | 10M | 20M | 2.9M | 202K | 47M | 187M |
| Total Assets | 19M | 12M | 21M | 6.0M | 4.5M | 52M | 191M |
| Total Liabilities | 2.6M | 1.3M | 1.4M | 3.1M | 4.3M | 5.0M | 3.3M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -109M | -117M | -130M | -148M | -168M | -190M | -249M |
| Working Capital | 16M | 9.7M | 19M | 2.3M | -249K | 47M | 187M |
| Current Assets | 19M | 11M | 21M | 4.8M | 3.7M | 52M | 190M |
| Current Liabilities | 2.6M | 1.1M | 1.4M | 2.5M | 4.0M | 4.9M | 2.8M |
| Per Share Data | |||||||
| EPS | 51.85 | -137.70 | -54.91 | -37.88 | -14.12 | -5.51 | -0.77 |
| Owner EPS | 60.74 | -16.56 | -54.18 | -6.65 | -1.76 | -1.93 | -1.37 |
| Book Value | 254.52 | 21.30 | 79.15 | 1.13 | 0.02 | 4.48 | 5.45 |
| Cash Flow/Share | 73.47 | -15.68 | -50.76 | -6.24 | -1.71 | -1.84 | -1.35 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.1M | 0.5M | 0.3M | 2.5M | 10.6M | 10.6M | 34.4M |
| Valuation | |||||||
| P/E Ratio | 3.7 | N/A | N/A | N/A | N/A | N/A | -17.2 |
| P/FCF | 2.8 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 0.8 | 6.5 | 0.9 | 22.5 | 222.1 | 1.6 | 2.4 |
| Price/Sales | 2.8 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | 35.2% | -11.5% | -70.2% | -24.5% | -40.2% | -26.5% | N/A |
| Market Cap | 12M | 67M | 19M | 65M | 45M | 74M | 455M |
| Avg. Price | 517.03 | 146.81 | 79.76 | 47.30 | 6.25 | 4.41 | 13.25 |
| Year-End Price | 190.99 | 138.38 | 73.53 | 25.50 | 4.25 | 6.99 | 13.25 |
Benitec Biopharma Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Benitec Biopharma Inc. (BNTC) has a 5-year average return on invested capital (ROIC) of -65.8%. This is below average and may indicate limited pricing power.
Benitec Biopharma Inc. (BNTC) has a market capitalization of $455M. It is classified as a small-cap stock.
Benitec Biopharma Inc. (BNTC) does not currently pay a regular dividend.
Benitec Biopharma Inc. (BNTC) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Benitec Biopharma Inc. (BNTC) generated $-20 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Benitec Biopharma Inc. (BNTC) has a debt-to-equity ratio of 0.11. This indicates a conservatively financed balance sheet.
Benitec Biopharma Inc. (BNTC) reported earnings per share (EPS) of $-5.51 in its most recent fiscal year.
Benitec Biopharma Inc. (BNTC) has a return on equity (ROE) of -94.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Benitec Biopharma Inc. (BNTC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Benitec Biopharma Inc. (BNTC) has a book value per share of $4.48, based on its most recent annual SEC filing.